Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902).
Harada T, Sasaki T, Ishii H, Takemoto S, Hisamatsu Y, Saito H, Yoneshima Y, Komiya K, Kashiwabara K, Naoki K, Ogawa T, Takeoka H, Saruwatari K, Ito K, Tsuchiya-Kawano Y, Mizuno K, Shimose T, Shioyama Y, Okamoto I. Harada T, et al. Among authors: shimose t. Thorac Cancer. 2024 Oct;15(29):2128-2135. doi: 10.1111/1759-7714.15444. Epub 2024 Sep 8. Thorac Cancer. 2024. PMID: 39245951 Free PMC article. Clinical Trial.
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study).
Kawachi H, Yamada T, Yoshimura A, Morimoto K, Iwasaku M, Tokuda S, Kim YH, Shimose T, Takayama K. Kawachi H, et al. Among authors: shimose t. Ther Adv Med Oncol. 2023 Jun 12;15:17588359231177022. doi: 10.1177/17588359231177022. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37333903 Free PMC article.
Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Ishii H, Azuma K, Shimose T, Yoshioka H, Kurata T, Shingu N, Okamoto M, Kawashima Y, Okamoto I. Ishii H, et al. Among authors: shimose t. Thorac Cancer. 2023 Jan;14(1):105-107. doi: 10.1111/1759-7714.14727. Epub 2022 Nov 15. Thorac Cancer. 2023. PMID: 36380738 Free PMC article.
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
Chihara Y, Takeda T, Goto Y, Nakamura Y, Tsuchiya-Kawano Y, Nakao A, Onoi K, Hibino M, Fukuda M, Honda R, Yamada T, Taniguchi R, Sakamoto S, Date K, Nagashima S, Tanzawa S, Minato K, Nakatani K, Izumi M, Shimose T, Kishimoto J, Uchino J, Takayama K. Chihara Y, et al. Among authors: shimose t. Oncologist. 2022 Nov 3;27(11):903-e834. doi: 10.1093/oncolo/oyac193. Oncologist. 2022. PMID: 36181763 Free PMC article. Clinical Trial.
A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401).
Samura H, Oki E, Okumura H, Yoshida T, Kai S, Kobayashi K, Kinjo T, Mori S, Tohyama T, Ohgaki K, Kawanaka H, Makiyama A, Ureshino N, Kotaka M, Shimose T, Ando K, Saeki H, Baba H, Maehara Y, Mori M. Samura H, et al. Among authors: shimose t. Cancer Chemother Pharmacol. 2020 Aug;86(2):285-294. doi: 10.1007/s00280-020-04108-x. Epub 2020 Jul 30. Cancer Chemother Pharmacol. 2020. PMID: 32734398 Clinical Trial.
31 results